Xilio Therapeutics Overview

  • Founded
  • 2016
Founded
  • Status
  • Private
  • Employees
  • 49
Employees
  • Latest Deal Type
  • Series C
  • Latest Deal Amount
  • $95M
Latest Deal Amount
  • Investors
  • 17

Xilio Therapeutics General Information

Description

Developer of tumor-selective immunotherapies intended for treating cancer. The company leverages proprietary technology to create an IO (immuno-oncology ) therapy that is activated selectively within the tumor while reducing toxicity throughout the body, enabling the medical community and patients to efficiently combat cancer.

Contact Information

Website
Formerly Known As
Akrevia Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 828 Winter Street
  • Suite 300
  • Waltham, MA 02451
  • United States
+1 (617) 000-0000

Xilio Therapeutics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Xilio Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series C) 24-Feb-2021 $95M 00000 Completed Generating Revenue
3. Early Stage VC (Series B) 02-Mar-2020 00000 00000 Completed Pre-Clinical Trials
2. Early Stage VC (Series A1) 27-Sep-2018 $22.5M $30M Completed Product Development
1. Early Stage VC (Series A) 12-Oct-2016 $7.5M $7.5M Completed Startup
To view Xilio Therapeutics’s complete valuation and funding history, request access »

Xilio Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of tumor-selective immunotherapies intended for treating cancer. The company leverages proprietary technology
Drug Discovery
Waltham, MA
49 As of 2021
00000
00000000000 00000

00000000

in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat n
0000 000000000
Brisbane, CA
00 As of 0000
000.00
000 0000-00-00
00000000000 000.00

000000 0

re magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip
0000000000000
South San Francisco, CA
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Xilio Therapeutics Competitors (7)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Maverick Therapeutics Venture Capital-Backed Brisbane, CA 00 000.00 00000000000 000.00
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
0000000 0000000000 Accelerator/Incubator Backed San Diego, CA 000000000000
00000000 000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
0000000 0000000000 Formerly VC-backed South San Francisco, CA 00 00000 00000000 00000
You’re viewing 5 of 7 competitors. Get the full list »

Xilio Therapeutics Executive Team (9)

Name Title Board Seat Contact Info
Rene Russo Ph.D Chief Executive Officer & Board Member
Timothy Clackson Ph.D President & Chief Technology Officer
Joe Farmer Chief Operating Officer
Martin Huber MD Chief Medical Officer
You’re viewing 4 of 9 executive team members. Get the full list »

Xilio Therapeutics Board Members (20)

Name Representing Role Since
Daniel Curran Takeda Ventures Board Member 000 0000
Daniel Lynch Self Chairman 000 0000
David Grayzel MD Atlas Venture Board Member 000 0000
Michael Ross Ph.D SV Health Investors Board Member 000 0000
Nancy Hong Ph.D RiverVest Venture Partners Board Member 000 0000
You’re viewing 5 of 20 board members. Get the full list »

Xilio Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Xilio Therapeutics Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Atlas Capital Ventures Family Office Minority 000 0000 000000 0
Bain Capital Life Sciences Corporate Venture Capital Minority 000 0000 000000 0
Deerfield Management Venture Capital Minority 000 0000 000000 0
RA Capital Management Venture Capital Minority 000 0000 000000 0
Rock Springs Capital Hedge Fund Minority 000 0000 000000 0
You’re viewing 5 of 17 investors. Get the full list »